Poster Session I - A153 PRELIMINARY RESULTS ON THE EFFECTIVENESS OF A MENTAL HEALTH PATHWAY FOR IBD

Abstract Background Patients with inflammatory bowel disease (IBD) experience high rates of depression, anxiety, and stress, negatively affecting quality of life, disease activity, and health care utilization. Despite this, mental health care remains under-integrated in IBD care. Aims The aim of this study is to evaluate the effectiveness of a mental health pathway for IBD, consisting of screening for anxiety and depression and incorporating digital tools for self-care. Methods This prospective, single-arm intervention study was conducted at two academic centers. Those who entered the pathway were introduced to digital self-management tools and completed questionnaires at baseline, 1, 2, and 3 months. Outcomes included depression (PHQ-9), anxiety (GAD-7), stress (PSSQ), fatigue (FACIT-F), quality of life (SIBDQ, WHO-5), and work productivity (WPAI). Linear mixed models evaluated longitudinal changes in participants who completed the 1-month follow-up, and Mann–Whitney U tests compared outcomes by disease activity. Results 116 participants were enrolled between May and Sept 2025. At 1 month, 56 participants (62.5% female, range 18-74) completed follow-up, 35 at 2 months, and 15 at 3 months. PHQ-9 improved across timepoints , with a 3.2-point reduction by 3 months. GAD-7 improved at all timepoints, with reductions of 4.3 points by 3 months. Participants with baseline PHQ-9 or GAD-7 ≥ 5 in comparison to < 5 had greater improvement at each time point. On average, PHQ-9 scores decreased by 45.1% overall and 46.5% among those with baseline ≥5, while GAD-7 scores decreased by 65.0% overall and 68.8% among those with baseline ≥5, exceeding established minimal clinically important difference (MCID) thresholds (≥5-point or ≥ 20% reduction). PSSQ decreased at all timepoints, FACIT-F improved at all timepoints, SIBDQ improved at 2 and 3 months, and WHO-5 at 3 months. No effects were seen for WPAI. At 1 month, patients with self-reported active disease showed higher anxiety (p = .016), stress (p = .005), fatigue (p = .050), and lower SIBDQ (p = .009) and WHO-5 (p = .008). At 2 months, active disease was linked to higher depression (p = .021), lower SIBDQ (p = .004), and higher fatigue (p = .044). Conclusions Interim results indicate that digital self-care tools were associated with clinically meaningful short-term improvements in depression, anxiety, stress, fatigue, and quality of life. Average reductions in PHQ-9 and GAD-7 scores exceeded published MCID thresholds, suggesting that observed changes reflect meaningful symptom improvement. Long-term outcomes (>3 months) remain to be evaluated. Funding Agencies Alberta Innovates, Northern Alberta Clinical Trials and Research Centre

Authors

Institutions

Publication Details

Journal
Journal of the Canadian Association of Gastroenterology
Published
2026-02-01
DOI
https://doi.org/10.1093/jcag/gwaf042.153
Primary Topic
Inflammatory Bowel Disease
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Poster Session I - A153 PRELIMINARY RESULTS ON THE EFFECTIVENESS OF A MENTAL HEALTH PATHWAY FOR IBD

Karen I. Kroeker, Ravneet Kaur, Brendan P. Halloran, Frank Hoentjen et al.
Journal of the Canadian Association of Gastroenterology
Inflammatory Bowel Disease
article

Poster Session I - A153 PRELIMINARY RESULTS ON THE EFFECTIVENESS OF A MENTAL HEALTH PATHWAY FOR IBD

Karen I. Kroeker, Ravneet Kaur, Brendan P. Halloran, Frank Hoentjen, K D Chappell, E Rahime, S Raiesdana, D Kao, F Peerani, B Elchitz, C Seow, M Gozdzik, Y Zhang, K Wong
article en

Abstract

Abstract Background Patients with inflammatory bowel disease (IBD) experience high rates of depression, anxiety, and stress, negatively affecting quality of life, disease activity, and health care utilization. Despite this, mental health care remains under-integrated in IBD care. Aims The aim of this study is to evaluate the effectiveness of a mental health pathway for IBD, consisting of screening for anxiety and depression and incorporating digital tools for self-care. Methods This prospective, single-arm intervention study was conducted at two academic centers. Those who entered the pathway were introduced to digital self-management tools and completed questionnaires at baseline, 1, 2, and 3 months. Outcomes included depression (PHQ-9), anxiety (GAD-7), stress (PSSQ), fatigue (FACIT-F), quality of life (SIBDQ, WHO-5), and work productivity (WPAI). Linear mixed models evaluated longitudinal changes in participants who completed the 1-month follow-up, and Mann–Whitney U tests compared outcomes by disease activity. Results 116 participants were enrolled between May and Sept 2025. At 1 month, 56 participants (62.5% female, range 18-74) completed follow-up, 35 at 2 months, and 15 at 3 months. PHQ-9 improved across timepoints , with a 3.2-point reduction by 3 months. GAD-7 improved at all timepoints, with reductions of 4.3 points by 3 months. Participants with baseline PHQ-9 or GAD-7 ≥ 5 in comparison to < 5 had greater improvement at each time point. On average, PHQ-9 scores decreased by 45.1% overall and 46.5% among those with baseline ≥5, while GAD-7 scores decreased by 65.0% overall and 68.8% among those with baseline ≥5, exceeding established minimal clinically important difference (MCID) thresholds (≥5-point or ≥ 20% reduction). PSSQ decreased at all timepoints, FACIT-F improved at all timepoints, SIBDQ improved at 2 and 3 months, and WHO-5 at 3 months. No effects were seen for WPAI. At 1 month, patients with self-reported active disease showed higher anxiety (p = .016), stress (p = .005), fatigue (p = .050), and lower SIBDQ (p = .009) and WHO-5 (p = .008). At 2 months, active disease was linked to higher depression (p = .021), lower SIBDQ (p = .004), and higher fatigue (p = .044). Conclusions Interim results indicate that digital self-care tools were associated with clinically meaningful short-term improvements in depression, anxiety, stress, fatigue, and quality of life. Average reductions in PHQ-9 and GAD-7 scores exceeded published MCID thresholds, suggesting that observed changes reflect meaningful symptom improvement. Long-term outcomes (>3 months) remain to be evaluated. Funding Agencies Alberta Innovates, Northern Alberta Clinical Trials and Research Centre

Journal of the Canadian Association of GastroenterologyVol. 9(Supplement_1)
University of Alberta (CA), University of Calgary (CA)
Openalex Percentile: Top 54%
Inflammatory Bowel Disease
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.